The IMBRAVE150[9] and ORIENT-32[57] studies confirmed that ICI+anti-VEGFR/VEGFA had longer PFS and OS than MKI, and ICI+anti-VEGFR/VEGFA significantly prolonged PFS compared to immune monotherapy in HCC patients in the G030140[58] study. This evidence concerns the gene VEGFA and hepatocellular carcinoma.